ArticleViruses2025
HCV Screening in a Sicilian Centre: A Descriptive Cohort Profile.
Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Missed confirmatory HCV RNA testing in anti-HCV-reactive patients and the role of reflex testing in improving completion of the hepatitis C diagnostic care cascade: a laboratory-based retrospective study.BMC infectious diseases · 2026Observational
- Hepatitis Free Hospital: Retrospective Results of an In-Hospital Project of Hepatitis C Virus Micro-Elimination.Viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatitis C virus (HCV) infection prevalence in Italy varies according to geographical areas and clusters of infection. Moreover, epidemiological studies are old, and the actual prevalence of HCV active infections is also affected by the use of direct-acting antiviral therapies (DAAs) that achieve sustained virologic response (SVR) in >95% of treated patients. We aimed to evaluate the prevalence of HCV infections in in- or outpatients referred to a Sicilian hospital. MATERIALS AND
methodsThe study was conducted in the Buccheri La Ferla Hospital, in Palermo (Sicily), from 1 November 2019 to March 2022. We consecutively screened for HCV infections all inpatients who were evaluated on admission to the ward and all outpatients who referred to the central laboratory. All patients were screened using serological detection of HCV antibodies.
resultsIn the entire cohort, 469 out of 15,550 patients (3%) showed anti-HCV positivity, and this rate progressively increased according to classes of age (0.4% for <40 yrs, 3% for 40-60 yrs, 4% for >60-80 yrs, and 6.4% for >80 yrs). Among patients with anti-HCV positivity, 44.3% were HCV-RNA negative, 39.2% had HCV-RNA not available, and 16.4% were HCV-RNA positive. In total, 44.1% of patients with HCV-RNA positivity underwent DAA-based antiviral therapy.
conclusionsHCV screening programs can be useful in identifying infected patients at risk of liver disease progression and/or infection spreading. The implementation of laboratory strategies based on HCV reflex testing, the activation of dedicated linkage-to-care plans, and a focus on higher-risk groups could increase the effectiveness of screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.